KKR & Co. Inc. arrives at its May 21 Q1 earnings announcement after a difficult month — the stock fell 5.4% on the week to $96.97, down more than 21% year-to-date, and now trades well below every major analyst price target on the Street.
The most striking signal in the data is not the short positioning — it is what insiders did when the stock was falling. Both co-CEOs, Joseph Bae and Scott Nuttall, bought shares in late February at prices between $87 and $103, collectively deploying over $21 million in open-market purchases. Two independent directors added another $6.7 million around the same time. Total net insider buying over the 90-day window reached roughly $51 million across 516,000 shares. That is a meaningful cluster of C-suite conviction purchases, all executed as the stock retreated from its highs, and all pointing in the same direction.
The short side tells a far less dramatic story. Short interest is low at 1.4% of the free float — not a level that typically drives price action in either direction. It did edge up 17.7% over the past month, with the bulk of that build occurring in mid-April, but it has since stabilised. Borrow is essentially free at 0.37%, down more than 21% over the past month. Availability remains ample, giving shorts no friction and no squeeze catalyst. The ORTEX short score of 30 is also modest, sitting in the 70th percentile for its sector — elevated enough to note, but not at an extreme. Options tell a slightly different story: the put/call ratio climbed to 1.45, close to 1.8 standard deviations above its 20-day mean of 1.32. The ratio has been drifting higher for a month, from around 1.1 in mid-April to current levels. That reflects a growing preference for downside protection, not necessarily an aggressive short thesis.
Analysts remain broadly constructive but have been cutting targets. The direction of travel since early April has been overwhelmingly lower. Goldman Sachs trimmed to $110 from $145, Morgan Stanley moved to $153 from $177, and Oppenheimer took a sharp cut to $140 from $187 — all while holding positive ratings. More recently, post the Q4 print, UBS bucked the trend and raised its target to $126 from $113, keeping a Buy. The mean target across the Street now sits near $125.80, implying roughly 30% upside from current levels. That gap between target and price reflects the scale of the year-to-date de-rating: the P/E multiple has contracted by more than half a point over the past 30 days to around 15.1x, and the price-to-book has compressed by 0.2x to 1.4x. Bulls point to KKR's diversified private-markets platform and the long-term earnings power of its insurance segment. Bears flag macro-driven headwinds to dealmaking, muted realisations, and the dilutive effect of recent executive stock vesting on future EPS.
The institutional base remains stable and heavily concentrated in insiders. George Roberts and Henry Kravis together hold over 18% of shares, with Kravis adding 150,000 shares in the most recently reported period. Capital Research, the largest active-manager holder at 6.85%, added 11.3 million shares as of April 30 — a notable addition that suggests at least one large active manager is treating the pullback as a buying opportunity. Wellington added 2.9 million shares through March, and T. Rowe Price added 9.8 million, though those figures reflect Q1 reporting windows.
KKR's last two earnings reactions have been negative: the stock fell 0.9% in one day and 3.4% over five days after the Q4 print in early May, and dropped 2.5% on the day and 3.7% over the following week after the prior release. With the stock already down more than 21% on the year, the setup into May 21 hinges on whether management's commentary on deployment pace, fee-related earnings growth, and the insurance segment can shift the narrative on forward estimates — which rank in just the 19th to 23rd percentile on EPS surprise and near-term momentum.
See the live data behind this article on ORTEX.
Open KKR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
